Big biotech, Big pharma, M&A

Roche creates M&A headlines with Intermune purchase

Posted on 26 August 2014

Tags: , , ,

Roche announced the M&A of Brisbane, California biotech company InterMune, Inc. for a cash transaction totaling $8.3 billion.

Based on a price of $74.00 per share, the M&A has been approved by the boards of both companies.

InterMune focuses on developing and commercializing therapies in pulmonology and orphan fibrotic diseases.

The M&A of InterMune would strength Roche’s portfolio of respiratory drugs.

Under the M&A deal, Roche will start a tender offer non later than August 29, 2014 and InterMune will file a statement of recommendation to shareholders.

For further deal information visit Current Agreements (subscription required)


Read: more on M&A deals in pharma, biotech, life science partnering deal news, insights and glossary

Report : Partnering Agreements with Roche 2009-2014

Report: Pharma and Biotech M&A Trends 2009-2014

Browse: Complete Current Partnering report catalog

View: Current Partnering’s M&A Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Partnering activity – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Parnering activity – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply